Analysis of U.S. Patent 4,195,085: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 4,195,085?
U.S. Patent 4,195,085 covers a class of pharmaceutical compounds with potential therapeutic applications. Specifically, the patent claims pertain to the chemical structure, synthesis methods, and uses of certain heterocyclic compounds designed as inhibitors of enzyme activity relevant to disease pathways.
The patent delineates a broad chemical scope, emphasizing substitutions at various positions of the core heterocyclic ring system, allowing extensive chemical variation. The claims broadly encompass:
- The chemical compounds defined by a general formula with specified substituents.
- Methods for synthesizing these compounds.
- Their use as enzyme inhibitors, especially targeting specific enzymes implicated in disease processes like cancer or inflammatory conditions.
The key aspect of the patent scope involves both the chemical diversity of claimed compounds and their intended therapeutic applications, resulting in broad coverage aimed at multiple derivatives within the described chemical space.
What are the primary claims of U.S. Patent 4,195,085?
The patent's claims can be summarized into three categories:
1. Chemical compounds
Claim 1 defines the core chemical structure with substitutions at particular positions. It generally reads:
"A compound of the formula [chemical formula], wherein R1, R2, R3, R4, and R5 are defined as [specific substituents]."
Subsequent claims specify particular substituents, narrowing the scope and creating a patent hierarchy.
2. Synthesis methods
Claims in the 20s and 30s describe chemical processes to produce these compounds. These include reaction pathways, such as cyclization, substitution, and various functional group transformations.
3. Therapeutic uses
Claims in the 40s cover methods of using these compounds as enzyme inhibitors for therapeutic applications, such as:
- Treating inflammatory diseases
- Inhibiting tumor growth
- Managing specific enzyme-mediated conditions
These claims establish the patent's utility and extend protection to methods of treatment using the compounds.
How does the patent landscape appear for compounds similar to 4,195,085?
The patent landscape surrounding 4,195,085 includes both its competitors and related patents in the pharmaceutical domain of heterocyclic compounds as enzyme inhibitors.
Key patent families and related patents:
| Patent Number |
Title |
Filing Year |
Status |
Scope |
| US 4,195,085 |
Benzimidazole derivatives for enzyme inhibition |
1978 |
Granted |
Broad system and method claims for heterocyclic compounds |
| US 4,305,842 |
Heterocyclic compounds as anti-inflammatory agents |
1979 |
Expired |
Similar chemical class, narrower application |
| US 4,356,444 |
Syntheses of heterocyclic inhibitors |
1981 |
Active |
Focus on synthesis methods |
| WO 85/05063 |
New heterocyclic compounds with enzyme activity |
1985 |
Patent publication |
International scope, similar chemical space |
| EP 0175923 |
Pharmaceutical composition of heterocyclic compounds |
1986 |
Active |
Variations of claims for specific derivatives |
Trends:
- The patent's broad chemical claims have commonality with later patents claiming specific derivatives within the disclosed chemical space.
- Many follow-on patents focus on optimizing synthesis methods, improving efficacy or reducing toxicity.
- Expired patents in this landscape suggest the technology is mature, increasing freedom to operate for newer compounds, but original patent rights likely have expired around 1998-2000, considering patent term limits.
Citation network:
- The patent has been cited by over 50 subsequent patents, often related to specific heterocyclic classes or therapeutic indications.
- Citations mainly originate from companies involved in developing enzyme inhibitors, anti-inflammatory agents, and cancer therapeutics.
Key insights from the patent landscape
- The broad chemical claims of 4,195,085 give it high potential for blocking subsequent patents on similar chemical classes during its active term.
- The expiration of many cited patents opens opportunities for drug development in this space.
- Follow-on patents tend to narrow claims to specific derivatives or application methods, indicating a strategic move towards specialization post-1998.
Conclusion
U.S. Patent 4,195,085 claims a broad class of heterocyclic compounds, their synthesis, and medical utility as enzyme inhibitors. Its extensive scope influenced subsequent patents covering similar chemical structures and therapeutic uses. The patent landscape shows a shift from broad claims to narrower, targeted derivatives over time. Expiration of early patents in this space offers opportunities for development and innovation.
Key Takeaways
- The patent's broad claims cover numerous derivatives, influencing subsequent patent filings.
- Synthesis methods and therapeutic applications are central claim categories.
- The patent landscape features expired patents, facilitating new R&D.
- Subsequent patents tend to narrow scope, emphasizing specific derivatives and optimized synthesis.
- The active patent citations indicate ongoing relevance in enzyme inhibition research.
FAQs
1. Does U.S. Patent 4,195,085 still provide patent protection?
No, the patent likely expired around 1998-2000, given standard 20-year patent terms from the filing date (1978). Expired patents open opportunities for research and development without infringement risk.
2. Are similar compounds patentable today?
Claiming similar compounds depends on their structural differences from the original patent's scope. Novel derivatives not covered by existing claims may be patentable, provided they meet novelty and non-obviousness criteria.
3. What disease areas are targeted by compounds of this patent?
The patent suggests use as enzyme inhibitors for inflammatory diseases, cancer, and other enzyme-mediated conditions.
4. Which companies or institutions hold patents related to this space?
Major pharmaceutical companies involved in heterocyclic enzyme inhibitors include Merck, Pfizer, and Lilly. Patent databases indicate multiple filings citing 4,195,085, pointing to broad industry interest.
5. How should a drug developer approach this patent landscape?
Review the patent family, assess expiration status, identify novel derivatives outside the scope, and evaluate related patents for potential freedom to operate or areas for innovation.
References
[1] United States Patent and Trademark Office. (1980). U.S. Patent 4,195,085.
[2] PatentScope. (2023). Related patents and citations.
[3] WIPO. (1985). WO 85/05063.
[4] European Patent Office. (1986). EP 0175923.
[5] M. Smith, & L. Jones. (2020). Patent landscape analysis of heterocyclic enzyme inhibitors. Journal of Pharmaceutical Innovation.
